Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy Market Outlook

The global Duchenne Muscular Dystrophy (DMD) market is projected to reach approximately USD 10 billion by 2033, growing at a compound annual growth rate (CAGR) of around 8.5% from 2025 to 2033. This growth can be attributed to several critical factors, including the increasing prevalence of DMD, advancements in research and treatment modalities, and enhanced awareness regarding the disease. Additionally, the rise in demand for novel therapies and treatment options such as gene therapy, exon skipping therapies, and steroids is accelerating market expansion. The growing number of clinical trials and investment by biotechnology companies in developing innovative treatments is expected to further propel market growth. Moreover, the increase in funding and initiatives by governments and organizations to support DMD research is also expected to have a positive impact on the market's trajectory.

Growth Factor of the Market

One of the significant growth factors for the Duchenne Muscular Dystrophy market is the rising awareness and diagnosis rate of the condition. As healthcare professionals become more educated about the symptoms and progression of DMD, early diagnosis is becoming increasingly common, leading to timely intervention and treatment. Furthermore, the advancement of genetic testing technologies has made it easier to identify DMD in children at an early stage, which opens up the opportunity for initiating treatment before the condition progresses severely. Additionally, the ongoing research for developing effective therapies, such as gene therapy and exon skipping, is not only creating hope among patients but also stimulating investment in the market. The increasing collaboration between pharmaceutical companies and research institutions is expected to lead to the discovery of new treatment options. Lastly, the rise in healthcare expenditure globally is allowing patients and families to access advanced and often costly treatments, thus driving market growth.

Key Highlights of the Market

• Projected market growth to USD 10 billion by 2033 with an 8.5% CAGR.
• Growing number of clinical trials focusing on innovative therapies.
• Increased awareness and early diagnosis leading to timely treatments.
• Significant investments from pharmaceutical companies in DMD research.
• Enhanced government initiatives and funding supporting DMD research.

By Product Type

Exon Skipping Therapies:

Exon skipping therapies represent a groundbreaking approach in treating Duchenne Muscular Dystrophy by facilitating the production of functional dystrophin protein, which is essential for muscle function. These therapies utilize synthetic drugs to skip over specific exons in the dystrophin gene, allowing for the creation of a shortened but functional version of the dystrophin protein. This innovative treatment has gained traction due to its potential to mitigate disease progression and improve muscle function in affected individuals. With several ongoing clinical trials investigating the efficacy and safety of exon skipping therapies, there is a burgeoning interest from pharmaceutical companies, contributing significantly to market growth.

Steroid Medications:

Steroid medications, particularly corticosteroids like prednisone and deflazacort, are widely used in managing Duchenne Muscular Dystrophy. These medications help in reducing inflammation and slowing muscle degeneration, resulting in an extension of ambulation and overall muscle strength in patients. The usage of steroids has been a cornerstone of DMD management for years, and their efficacy in prolonging muscle function has been well documented. However, the side effects associated with long-term steroid use, such as weight gain and potential growth suppression, have led to ongoing research into alternative therapies that could confer similar benefits without the adverse effects, thereby stimulating innovations in the segment.

Assistive Devices:

Assistive devices play a vital role in enhancing the quality of life for individuals with Duchenne Muscular Dystrophy. These devices, including mobility aids such as wheelchairs, braces, and standing frames, are designed to support patients in maintaining independence and mobility as their condition progresses. The increasing prevalence of DMD, coupled with the growing awareness of assistive technology's benefits, is driving demand in this segment. Furthermore, advancements in technology are leading to the development of more sophisticated assistive devices that are tailored to address the specific mobility challenges faced by DMD patients, thus expanding the market for these products.

Gene Therapy:

Gene therapy represents one of the most promising advancements in the treatment of Duchenne Muscular Dystrophy, targeting the underlying genetic cause of the disease. This innovative approach involves delivering modified genes into the patient’s muscle cells to produce functional dystrophin, thereby addressing the fundamental defect in DMD. Clinical trials are currently underway to evaluate the safety and efficacy of various gene therapy strategies, generating significant excitement and investment in this segment. The potential for gene therapy to offer curative solutions rather than symptomatic relief positions it as a critical area of focus for both researchers and healthcare providers, driving market growth.

Others:

The 'Others' category in the Duchenne Muscular Dystrophy market includes a range of treatment modalities and supportive therapies that do not fall into the primary categories mentioned above. These may encompass nutritional supplements, physical therapy interventions, and emerging pharmacological agents aimed at improving muscle health and function. As the understanding of Duchenne muscular dystrophy grows, research into alternative and adjunct therapies continues to evolve. This segment is seeing increased interest, as novel treatment combinations are explored to provide a comprehensive approach to managing DMD, thus further fostering market expansion.

By Application

Hospitals:

Hospitals are a primary application area for Duchenne Muscular Dystrophy treatments, offering comprehensive care that includes diagnosis, treatment, and ongoing management of the disease. In hospitals, multidisciplinary teams comprising neurologists, physiotherapists, and other specialists collaborate to provide individualized care to DMD patients. The availability of advanced diagnostic tools within hospitals ensures timely identification and intervention, which are crucial for improving patient outcomes. Additionally, hospitals facilitate access to clinical trials for new therapies, further enhancing their role as pivotal institutions in the treatment landscape of DMD.

Clinics:

Clinics specializing in muscular dystrophies serve as essential treatment centers for patients with Duchenne Muscular Dystrophy. These facilities often provide focused care, including physical therapy, occupational therapy, and nutritional counseling tailored specifically for DMD patients. Clinics are instrumental in managing the complexities of the disease and providing personalized treatment plans that address the unique challenges faced by patients. The trend of outpatient care is stimulating the growth of clinics as they become more integral to the continuum of care for DMD, allowing for continuous monitoring and adjustments to treatment as necessary.

Rehabilitation Centers:

Rehabilitation centers offer specialized programs for individuals with Duchenne Muscular Dystrophy, focusing on enhancing functional abilities and quality of life. These centers provide therapeutic interventions such as physical therapy, occupational therapy, and speech therapy, aiming to maximize the independence and mobility of DMD patients. The increasing recognition of the importance of rehabilitation in managing chronic conditions like DMD is driving the demand for these facilities. Furthermore, rehabilitation centers often collaborate with other healthcare providers, ensuring a comprehensive approach to care that significantly impacts patients' overall well-being and functional outcomes.

Others:

The 'Others' category within the application segment encompasses various settings that provide care and support for individuals with Duchenne Muscular Dystrophy. This may include home healthcare services, community health programs, and non-profit organizations focused on supportive care and education. These services are crucial as they facilitate ongoing support for DMD patients and their families, allowing for better management of daily life challenges associated with the condition. The rise in awareness and advocacy for Duchenne Muscular Dystrophy is driving growth in this segment, as more resources and programs are developed to support affected individuals.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a significant role in the distribution of medications for Duchenne Muscular Dystrophy, providing a crucial access point for patients receiving inpatient care. These pharmacies often have a closer relationship with healthcare providers, enabling them to manage complex medication regimens effectively and ensure that patients receive timely doses of necessary therapies. Moreover, hospital pharmacies are vital in providing specialized medications that may not be available through retail channels, ensuring that patients have access to the latest treatment options as they become available. The integrated approach of hospital pharmacies enhances the overall management of DMD, making them an essential part of the healthcare ecosystem.

Retail Pharmacies:

Retail pharmacies serve as a common distribution channel for Duchenne Muscular Dystrophy medications, providing patients with convenient access to prescribed therapies. These pharmacies are often the first point of contact for patients and families seeking treatments and supportive care products. The growing emphasis on patient-centered care and the convenience of retail pharmacies facilitate a seamless experience for patients managing chronic conditions like DMD. Furthermore, retail pharmacies are increasingly offering medication counseling, adherence programs, and educational resources, thus enhancing the overall support provided to DMD patients and their families.

Online Pharmacies:

Online pharmacies are emerging as a significant distribution channel for medications related to Duchenne Muscular Dystrophy, particularly in the wake of increased digitalization in healthcare. These platforms offer convenience for patients and caregivers seeking to manage prescriptions and refill medications from the comfort of their homes. The rise in telehealth services and the growing popularity of e-commerce present an opportunity for online pharmacies to cater specifically to the DMD community by providing specialized products and resources. Additionally, the ability to compare prices and access a wider range of products makes online pharmacies an attractive option for individuals managing the complexities of DMD treatment.

Others:

The 'Others' category within the distribution channel segment refers to alternative pathways through which Duchenne Muscular Dystrophy treatments may be accessed. This could include specialty distribution centers, compounding pharmacies that create personalized medications, or direct-to-consumer channels facilitated by manufacturers. As the landscape of pharmaceutical distribution evolves, these alternative channels are becoming increasingly important in ensuring that patients have access to necessary therapies. The trend towards personalized medicine and patient-centered care is driving the growth of these alternative distribution methods, ultimately benefiting individuals living with DMD.

By Ingredient Type

Dystrophin:

Dystrophin is a critical protein that plays a vital role in maintaining muscle cell integrity, and its absence is the root cause of Duchenne Muscular Dystrophy. Treatments focusing on dystrophin replacement or restoration are at the forefront of DMD research. Approaches such as gene therapy aim to deliver the dystrophin gene to muscle cells, allowing for the production of this essential protein. The significant advancements in understanding the molecular biology of dystrophin have led to innovative therapeutic strategies, making this ingredient type a key focus in the DMD treatment landscape. The potential to restore dystrophin levels in patients marks a transformative approach to managing this debilitating condition.

Myostatin Inhibitors:

Myostatin inhibitors are a promising class of therapeutic agents being explored in the context of Duchenne Muscular Dystrophy. Myostatin is a protein that inhibits muscle growth, and its inhibition could lead to an increase in muscle mass and strength, which is crucial for DMD patients. Research into myostatin inhibitors is gaining momentum, with ongoing clinical trials assessing their efficacy and safety in DMD populations. The potential for these inhibitors to enhance muscle regeneration and slow the progression of muscle degeneration makes them a critical area of focus and a significant contributor to the market.

Utrophin Modulators:

Utrophin modulators are another innovative therapeutic approach in the Duchenne Muscular Dystrophy market, aimed at compensating for the absence of dystrophin. Utrophin, a protein that shares similarities with dystrophin, can potentially substitute for its function in muscle cells, providing an alternative pathway for muscle protection and maintenance. Research is underway to explore how enhancing utrophin expression can benefit DMD patients and improve muscle function. The development of utrophin modulators represents an exciting advancement in the therapeutic landscape for DMD, with the potential to offer new hope to those affected by the condition.

Anti-inflammatory Drugs:

Anti-inflammatory drugs are commonly used in the management of Duchenne Muscular Dystrophy to address the chronic inflammation associated with muscle degeneration. Corticosteroids, in particular, have been widely prescribed to help slow the progression of the disease and preserve muscle function. The therapeutic effects of anti-inflammatory medications have been well-established in DMD management, although their long-term use is often accompanied by side effects. Ongoing research into alternative anti-inflammatory strategies aims to enhance treatment efficacy while minimizing adverse effects, ensuring a comprehensive approach to managing inflammation in DMD patients.

Others:

The 'Others' category in ingredient types encompasses various compounds and formulations that may not fit into the primary categories but still play a role in the management of Duchenne Muscular Dystrophy. This can include nutritional supplements, alternative therapies, or emerging pharmacological agents that are being explored for their potential benefits in supporting muscle health and overall well-being. As research continues to evolve, this segment holds promise for discovering new adjunct therapies that can enhance the existing treatment landscape for DMD patients, providing a holistic approach to managing the condition.

By Region

The North American region is currently leading the Duchenne Muscular Dystrophy market, accounting for approximately 40% of the global market share. The high prevalence of DMD, coupled with advanced healthcare infrastructure and significant investment in research and development, positions North America as a key player in the market. The presence of major pharmaceutical companies and ongoing clinical trials for innovative therapies further contribute to market growth in this region. Additionally, supportive government policies and increased funding for DMD-related research are expected to sustain the upward trajectory of the market in North America, with a projected CAGR of 9% through the forecast period.

Europe holds the second-largest market share in the Duchenne Muscular Dystrophy market, contributing around 30% to the global revenue. The increasing awareness of DMD, coupled with improved diagnostic capabilities, has led to a rise in treatment initiation across the region. European countries are also witnessing a surge in clinical trials aimed at exploring novel therapies for DMD, with a focus on personalized medicine approaches. The collaboration between research institutions and pharmaceutical companies is driving innovation and expanding treatment options for patients. Despite some challenges, such as regulatory hurdles and healthcare disparities among member states, the European market is projected to experience steady growth in the coming years, thereby consolidating its position in the global landscape.

Opportunities

One significant opportunity in the Duchenne Muscular Dystrophy market lies in the development of gene therapies, which have the potential to revolutionize the treatment landscape for this rare genetic disorder. As research advances and more clinical trials yield promising results, the market for gene therapies is poised for significant growth. Companies specializing in genetic engineering are increasingly investing in technologies that can effectively deliver therapeutic genes to muscle cells, making gene therapy an attractive horizon for innovation. The potential for curative approaches that address the root cause of DMD rather than just managing symptoms creates a responsive market environment where stakeholders can capitalize on the changing dynamics of DMD treatment.

Another opportunity exists in the growing emphasis on patient-centric care models and multidisciplinary treatment approaches. As the understanding of Duchenne Muscular Dystrophy expands, the healthcare system is moving towards more integrative care that encompasses not only pharmacological interventions but also rehabilitation, nutritional support, and mental health services. This shift creates a unique opportunity for healthcare providers and pharmaceutical companies to develop comprehensive care packages that address the diverse needs of DMD patients. By focusing on holistic treatment options that improve overall quality of life, stakeholders can tap into a market that emphasizes tailored and supportive care solutions, thereby fostering patient loyalty and enhancing therapeutic outcomes.

Threats

One of the notable threats facing the Duchenne Muscular Dystrophy market is the regulatory challenges associated with the approval of new therapies. The complexity of DMD as a genetic disorder often leads to lengthy and rigorous evaluation processes for novel treatments, posing a barrier to timely market entry. Additionally, the stringent requirements for demonstrating safety and efficacy may deter smaller companies from pursuing innovative therapies. This situation can stifle innovation and limit the availability of potentially life-altering treatments for patients, ultimately hindering market growth. Furthermore, the high costs associated with the development and commercialization of new therapies may result in limited access for patients, creating disparities in treatment availability.

Another pressing concern is the potential for high competition within the Duchenne Muscular Dystrophy market, particularly as more companies recognize the lucrative opportunities presented by DMD treatments. The influx of new entrants may lead to market saturation, which can drive down prices and impact profit margins for existing players. Moreover, the rapid evolution of treatment modalities means that companies must continuously innovate to maintain their competitive edge. This ongoing competition may result in increased pressure on research and development budgets, which could limit resources for exploring groundbreaking therapies. The interplay of these market dynamics creates a landscape fraught with challenges that stakeholders must navigate carefully.

Competitor Outlook

• BioMarin Pharmaceutical Inc.
• Sarepta Therapeutics, Inc.
• Pfizer Inc.
• Vertex Pharmaceuticals Incorporated
• Solid Biosciences Inc.
• Novartis AG
• GlaxoSmithKline plc
• Santhera Pharmaceuticals Holding AG
• Catabasis Pharmaceuticals, Inc.
• Wave Life Sciences Ltd.
• Roche Holding AG
• Astellas Pharma Inc.
• Boehringer Ingelheim
• CRISPR Therapeutics AG
• Vertex Pharmaceuticals Incorporated

The competitive landscape of the Duchenne Muscular Dystrophy market is characterized by a mix of established pharmaceutical companies and innovative biotech firms, all vying for a share of this growing market. Major players like BioMarin and Sarepta Therapeutics are investing heavily in research and development, focusing on novel treatment modalities such as gene therapies and exon skipping to provide effective solutions for DMD patients. This competitive environment is further fueled by the increasing number of clinical trials and partnerships between companies and academic institutions aimed at advancing DMD research. The high stakes involved in bringing novel therapies to market drive collaboration and competition, creating a dynamic landscape where innovation is paramount.

BioMarin Pharmaceutical Inc. is one of the leading players in the DMD market, known for its pioneering work in enzyme replacement therapies and gene therapies. The company's commitment to developing comprehensive treatment options has positioned it as a key player in the DMD space. Its robust pipeline, which includes innovative therapies targeting the underlying genetic causes of DMD, continues to attract significant investment and collaboration opportunities. Moreover, BioMarin's efforts in patient advocacy and education underscore its dedication to improving the lives of individuals affected by DMD.

Sarepta Therapeutics, Inc. is another major contender in the Duchenne Muscular Dystrophy market, focusing on developing targeted genetic therapies. The company's innovative approaches, particularly in exon skipping technology, have garnered significant attention in the medical community. Sarepta's commitment to advancing DMD research and collaborating with industry leaders has allowed it to maintain a competitive edge in this fast-evolving landscape. The successful outcomes from its clinical trials have positioned Sarepta as a frontrunner in the quest for effective DMD treatments, making it a critical player in the market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Novartis AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Pfizer Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Roche Holding AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 GlaxoSmithKline plc
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Astellas Pharma Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Boehringer Ingelheim
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 CRISPR Therapeutics AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Solid Biosciences Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Wave Life Sciences Ltd.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Sarepta Therapeutics, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 BioMarin Pharmaceutical Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Catabasis Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Santhera Pharmaceuticals Holding AG
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Vertex Pharmaceuticals Incorporated
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Duchenne Muscular Dystrophy Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Rehabilitation Centers
    • 6.1.4 Others
  • 6.2 Duchenne Muscular Dystrophy Market, By Product Type
    • 6.2.1 Exon Skipping Therapies
    • 6.2.2 Steroid Medications
    • 6.2.3 Assistive Devices
    • 6.2.4 Gene Therapy
    • 6.2.5 Others
  • 6.3 Duchenne Muscular Dystrophy Market, By Ingredient Type
    • 6.3.1 Dystrophin
    • 6.3.2 Myostatin Inhibitors
    • 6.3.3 Utrophin Modulators
    • 6.3.4 Anti-inflammatory Drugs
    • 6.3.5 Others
  • 6.4 Duchenne Muscular Dystrophy Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Duchenne Muscular Dystrophy Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Duchenne Muscular Dystrophy market is categorized based on

By Product Type

• Exon Skipping Therapies
• Steroid Medications
• Assistive Devices
• Gene Therapy
• Others

By Application

• Hospitals
• Clinics
• Rehabilitation Centers
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Dystrophin
• Myostatin Inhibitors
• Utrophin Modulators
• Anti-inflammatory Drugs
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• BioMarin Pharmaceutical Inc.
• Sarepta Therapeutics, Inc.
• Pfizer Inc.
• Vertex Pharmaceuticals Incorporated
• Solid Biosciences Inc.
• Novartis AG
• GlaxoSmithKline plc
• Santhera Pharmaceuticals Holding AG
• Catabasis Pharmaceuticals, Inc.
• Wave Life Sciences Ltd.
• Roche Holding AG
• Astellas Pharma Inc.
• Boehringer Ingelheim
• CRISPR Therapeutics AG
• Vertex Pharmaceuticals Incorporated